(Alliance News) - Blue-chip stock prices in Europe closed lower on Wednesday, as a decent start to the week gave way to some caution ahead of earnings from New York listing Nvidia, which has been at the heart of an artificial intelligence boom. Read More
(Alliance News) - Angle PLC on Wednesday said its annual loss narrowed in 2024 as revenue rose and operating costs fell, though the company warned that market uncertainty and funding cuts were weighing on revenue so far this year. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - London opened in the green on Wednesday as UK grocery sales climbed on warm spring weather, and Ukrainian President Volodymyr Zelensky suggests a trilateral meeting with the US and Russia. Read More
(Alliance News) - Angle PLC on Friday said the results of an Eisai Co Ltd pilot study supported the capability of the Parsortix system for real-time assessment of breast cancer patient HER2 status. Read More
(Alliance News) - Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour cell DNA workflow, using Illumina Inc's sequencing technology for the first time. Read More
(Alliance News) - Angle PLC on Thursday said it expected losses to have narrowed in 2024, but its share price suggested lingering market wariness. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - Stocks were called lower in London on Thursday, after a disappointing report on UK consumer confidence. Read More
(Alliance News) - Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patients, and will soon present positive data for a breast cancer testing kit. Read More
(Alliance News) - Stock prices in London were mostly higher at midday on Friday, despite disappointing data including weaker-than-expected gross domestic product growth. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More
(Alliance News) - Angle PLC on Monday said its in-vitro diagnostic Parsortix system was successfully used in a non-small cell lung cancer study to help identify patients becoming resistant to treatment. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Angle PLC - Guildford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a clinical-stage biotech company. It will launch with a fully-funded pilot study. Further details are confidential between the two companies. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Celebrates research data on its Parsortix PC1 system that it says supports approval by the US Food & Drug Administration. Data was published as a peer-reviewed publication in the Journal of Experimental & Clinical Research. The study had been submitted to the FDA for De Novo clearance of the Parsortix PC1 system. The De Novo process provides a pathway to classify some novel medical devices. The study reports that the Parsortix system successfully captured and harvested circulating tumour cells (CTC) from metastatic breast cancer patient blood samples for downstream analysis using immunofluorescence and cytological evaluation. Angle says the publication validates the use of the Parsortix system for CTC isolation and harvest in metastatic breast cancer. Read More
Angle PLC - Guildford, England-based liquid biopsy company - Receives valid applications for a total of 3.6 million open offer shares from qualifying shareholders, pursuant to open offer announced on June 5. Says that the open offer has raised gross proceeds of GBP500,000 at the issue price, which will be used to strengthen Angle's balance sheet. Adds that in aggregate, GBP9.3 million gross proceeds have been raised, pursuant to the placing, subscription, and open offer. Read More